SM1-71

• Description:

  SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines[1][2][3].

• UNSPSC:

  12352005

• Target:

  FGFR; LIM Kinase (LIMK) ; MAP3K; Ribosomal S6 Kinase (RSK) ; Src

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sm1-71.html

• Purity:

  96.09

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  C=CC(NC1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC=C2Cl)=O

• Molecular Formula:

  C24H26ClN7O

• Molecular Weight:

  463.96

• References & Citations:

  [1]Rao S, et, al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019 Jun 20; 26 (6) : 818-829.e9.|[2]Rao S, et, al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem. 2019 May 24;294 (21) :8664-8673.|[3]Tan L, et, al. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 Feb 1; 25 (3) : 838-846.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  LIMK1; RSK2

• CAS Number:

  [2088179-99-9]